Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
September 23, 2024 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
September 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...
Monster Digital Adds Significant Digital Production Capacity with the Adoption of 10 Additional Kornit Apollo Systems During 2025
September 23, 2024 08:00 ET
|
Kornit Digital Ltd
On demand manufacturer serves the world’s largest global brands, retailers and e-commerce platformsOperates three locations, nearshore and onshore, running 24/7, promoting new product delivery and...
The Oncology Institute Announces CFO Transition
September 23, 2024 08:00 ET
|
Toi Management, LLC
CERRITOS, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), today announced that Chief Financial Officer, Mihir Shah, will transition...
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
September 23, 2024 08:00 ET
|
Assembly Biosciences, Inc.
– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both...
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
September 23, 2024 08:00 ET
|
Actuate Therapeutics
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential to Activate the Immune System Even in...
Nano Dimension Acquisition of Desktop Metal Receives Support from Leading Proxy Advisory Firm - ISS
September 23, 2024 08:00 ET
|
Nano Dimension Ltd.
Institutional Shareholder Services Recommends That Desktop Metal’s Shareholders Vote For the Company’s Proposals Merger Agreement Announced July 3rd, 2024 For Nano Dimension to Acquire Desktop...
New Family of Voltage-Controlled Saw Oscillators with Ultra-Low Phase Noise Performance for Radar Applications
September 23, 2024 08:00 ET
|
Microchip Technology Inc.
CHANDLER, Ariz., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mission-critical applications like radar and test and measurement require specialized components with precise frequency control and ultra-low...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
September 23, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
September 23, 2024 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...